**REGISTERED CHARITY NUMBER: 0276829** 

## **REPORT OF THE TRUSTEES AND** 

**UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2021** 

## **FOR** 

**BRITISH ASSOCIATION FOR CYTOPATHOLOGY** 

Ellis Atkins Chartered Accountants The Atrium Business Centre Curtis Road Dorking Surrey RH4 1XA 



**BRITISH ASSOCIATION FOR CYTOPATHOLOGY** 

**CONTENTS OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2021** 

|||**Page**||
|---|---|---|---|
|**Report of the Trustees**|1|to|5|
|**Independent Examiner's Report**||6||
|**Statement of Financial Activities**||7||
|**Balance Sheet**||8||
|**Notes to the Financial Statements**|9|to|14|
|**Detailed Statement of Financial Activities**||15||





## **BRITISH ASSOCIATION FOR CYTOPATHOLOGY** 

## **REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 MARCH 2021** 

The trustees present their report with the financial statements of the charity for the year ended 31 March 2021. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019). 

## **OBJECTIVES AND ACTIVITIES** 

## **Objectives and aims** 

The British Association of Cytopathology (BAC), which is registered as a charity, was founded in 2011 resulting from the merger of British Society for Clinical Cytology (BSCC) and the National Association of Cytologists (NAC). The BAC exists to advance the science and art of Cytopathology by encouraging higher standards in Cytopathology for the benefit of the public and to encourage research in Cytopathology and related fields for the publication of useful results. In pursuit of these aims and objectives, the BAC has the power to receive contibutions via a membership fee and raise funds where appropriate, to finance the work of the BAC. 

To achieve these aims and objectives, the BAC will hold regular Scientific Meetings, educational study days, training courses and workshops and will facilitate a Continuous Education Certificate scheme open to all members. The BAC will work with groups of a similar nature and exchange information, advice and knowledge with them, including cooperation with other professional bodies, charities, statutory and non-statutory organisations. 

## **Significant activities** 

All the members receive the official journal "Cytopathology" as well as the regular magazine "SCAN". "SCAN" is  now published online and will be incorporated into "Cytopathology" going forward. The aim of Cytopathology is to publish articles relating to those aspects of cytology which will increase our knowledge and understanding of the aetiology, diagnosis and management of human disease. It contains original articles and critical reviews on all aspects of clinical cytology in its broadest sense: including gynaecological and non-gynaecological cytology, fine needle aspiration and screening strategy. The journal welcomes papers on ultrastructural, histochemical and immunocytochemical studies of the cell as well as articles on quantitative cytology and DNA hybridization. 

The aim of Cytopath Editorial policy reflects the interest of cytopathologists and cytotechnologists alike as well as the interest of clinicians using the cytology service. It also reflects the interest of biological scientists whose work involves research of the cellular level. We continue to correlate information on matters cytological including progress of the NHS Cervical Screening Programme. 

All members receive the journal 

## **Public benefit** 

The trustees confirm that they have referred to the guidance contained in the Charity Commissioner's general guidance on public benefit when reviewing the Charity's aims and objectives and in planning future activities. 

The trustees are satisfied that the charity continues to meet the required public benefit test through its objectives and activities described above. 

Page 1 



**BRITISH ASSOCIATION FOR CYTOPATHOLOGY** 

## **REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 MARCH 2021** 

## **ACHIEVEMENT AND PERFORMANCE Charitable activities** 

## www.britishcytology.org.uk 

The website continues to develop and covers the evolvement of the BAC, meetings and news/research within the field of Cytopathology. The BAC is keen to develop an educational section using cases/modules for self learning. We encourage any comments or ideas for developing the website and are particularly interested to hear if you have any material that would provide a valuable resource to our members. There are plans to review the website to create a more friendly user interface and use more images. 

## Continuing Education Scheme 

Since the merger of the BSCC and NAC, the Continuing Education Scheme developed by the NAC has been adopted as part of the BAC. It provides a means of recording on-going educational activities carried out by cytology screeners and biomedical scientists. Members of the scheme submit evidence to gain a certificate of achievement after attainment of a specified number of credits within a defined time frame. 

BAC have worked hard to establish ourselves as a professional body for cytopathology in the UK, and it has taken some time, but through working closely with other relevant organizations, national bodies, government departments we are now the 'go-to' body which represents cytology in all its forms within the UK, recognized and respected across the world. 

Due to COVID- 19 restrictions, the BAC has continued its educational meetings in the form of Webinars hosted through Zoom. These have been very well-received and have attracted many attendees not only from the UK but overseas too. The Webinars have been recorded and can be found on 'YouTube'. 

The BAC Twitter account is being widely used and the number of followers has increased greatly over the year. 

## **FINANCIAL REVIEW** 

## **Financial position** 

The Association has generated a surplus in the year of £12,757 (2020: £7,157 deficit) from its activities throughout the year. 

The revised arrangements for our journal Cytopathology continue to generate increased royalty payments from the publishers Wiley. However, the surpluses realised from Conferences and meetings in recent years are now of much increased importance to the finances of the BAC. No conference was held in this financial year. 

At the year end, the BAC still has available reserves in excess of £400,000 which we consider to be in line with the reserves policy referred to below. 

Executive is satisfied with the results shown, which are very much in line with expectations. 

## **Investment policy and objectives** 

The Constitution of the BAC authorises the Executive to make and hold investments using the funds of the charity. 

Cash balances are currently held with Lloyds Bank and The National Savings Bank. In addition, the BAC holds certain investments in quoted securities, which have been previously donated to it. 

Executive, having regard to the liquidity requirements of the organisation have operated a policy of keeping available funds within interest bearing deposit accounts. 

## **Reserves policy** 

The BAC maintains reserves to enable us to provide an uninterrupted service to our members. It is considered that reserves should be able to support a minimum of one year, and ideally up to two years operating costs. The BAC now has total reserves of £414,731 (2020: £401,974), and this is within the range of our reserves policy. 

Page 2 



## **BRITISH ASSOCIATION FOR CYTOPATHOLOGY** 

## **REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 MARCH 2021** 

## **FUTURE PLANS** 

As can be seen from the narrative above, we have many ideas and initiatives to promote our objectives. Our aims are to increase our social media presence and we have set up a media sub-committee. The aims of this group are to raise our profile and to revamp the website 

## Challenges 

This year continues where last year left off with the Covid-19 global pandemic. The BAC has continued to adapt the  way we work to enable us to carry on business as (un)usual by holding executive meetings via video conferencing platforms and providing live educational webinars (free of charge). 

## Cytology Education 

We have commenced a schedule of live webinars and so far held 4 with more planned for the coming year, covering a wide range of topics and areas of expertise. BAC has invested in the Zoom platform to host these sessions, and Dr Ash Chandra has provided his invaluable experience to enable us to do so. Feedback so far has been amazing. 

Some major cytology events in 2020 and 2021 that BAC were to be involved with have been cancelled or postponed but will hopefully go ahead in 2022 such as hosting another IAC tutorial in London as the last one in 2018 was so successful and well attended. 

The BAC spring tutorial had to be cancelled again but we are hoping to go ahead in 2022. We had a successful face to face ASM/AGM in Nottingham in October 2021 where we celebrated the 10th anniversary of the BAC. 

## The next 10 years 

The BAC will only continue to exist as long as it provides what the members want, and the executive will strive to provide this for as long as we can, but the future is ultimately in the hands of the membership. 

We will continue to develop the partnerships we have developed with other professional bodies such as the RCPath and the Institute of Biomedical Science (IBMS), so that the voice of the BAC is heard far and wide, but we do need new people on the executive to carry this work on, for the benefit of all members. Being an executive member is not a paid job, and on occasions requires some input from your own time, but is so interesting and rewarding that you will not mind. There are a lot of highly skilled, motivated and enthusiastic cytologists out there please consider bringing this to the BAC! 

## **STRUCTURE, GOVERNANCE AND MANAGEMENT** 

## **Governing document** 

The British Association for Cytopathology (BAC) was formed in 2011 following the merger of the British Society for Clinical Cytology (BSCC) and the National Association of Cytologists (NAC). BAC is a registered charity, charity number 276829, duly constituted under a Deed of Trust. The constitution and Rules were adopted on 25th September 1978, amended on 12th September 1982, 19th September 1990, 18th September 1991, 15th September 1998, 12th September 2006, 15th July 2011 and 15th September 2012. 

## **Appointment to Executive** 

Executive members are appointed for a period of three years, and are appointed by a majority vote from nominations received at the Annual Meeting.  The Officers of the BAC are selected from the Executive. 

The AGM of 4th November 2017 approved some changes to The BAC Constitution, which are available on the BAC website. The major change was the expansion of the Executive to 12 elected members plus the President. 

For the purposes of the Charities Act the officers and members of the BAC effectively act as the Charitable Trustees. 

Page 3 



**BRITISH ASSOCIATION FOR CYTOPATHOLOGY** 

## **REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 MARCH 2021** 

## **STRUCTURE, GOVERNANCE AND MANAGEMENT** 

## **Organisation** 

The charity is based within the UK. It no longer has any permanent office accommodation of its own but its administration is handled through IBMS in London. The academic work of the organisation is controlled and organised through a series of committees, the membership of which is shown below. 

We now have a "front desk" manned throughout the full working week through arrangements with IBMS in London. The remaining administrative duties have been devolved to members of The Executive. 

## **Induction and training of new members** 

New members of the Executive are briefed on their legal obligations under charity law, the committee, and decision making processes of the Organisation. 

## **Risk management** 

The Executive is responsible for safeguarding the assets of the BAC and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities and to provide reasonable assurance that: 

a) the BAC is operating efficiently and effectively; 

b) its assets are safeguarded against unauthorised use or disposition; 

c) proper records are maintained and are reliable; 

d) the BAC complies with relevant laws and regulations 

The systems of internal control are designed to provide reasonable, but not absolute, assurance against material misstatement or loss.  They include: 

e) regular meetings and reviews conducted by the Executive 

f) regular consideration by the Executive of the financial results in light of known expectations, non-financial performance indicators and review; 

g) delegation of authority and segregation of duties; 

h) identification and management of risks. 

The Executive actively review the main risk which the charity faces on a regular basis, and believe that maintaining our free reserves at the levels stated below, combined with our annual review of the controls over key financial systems carried out through various reviews, will provide sufficient resources in the event of adverse conditions. The Executive have also examined other operational and business risks which we face, and confirm that they have established systems to mitigate the significant risks.The Executive wish to ensure that the BAC's internal financial controls in particular, conform to guidelines issued by the Charity Commission. 

## **REFERENCE AND ADMINISTRATIVE DETAILS Registered Charity number** 

0276829 

## **Principal address** 

12 Coldbath Square London EC1R 5HL 

## **Trustees** 

Dr P Cross Prof  A Wilson Mrs K Ellis Mrs S Mehew Mrs A Cropper Dr A Maddox 

Page 4 



BIUTISII ASSOCIATION b￿R Cyl￿PATI10LoGy
REPORT oTr""riiF:'rRUStELS
b￿R THE YEAR b.liD￿.D 31 NLiRC1121121
REFERENCE AND ADMINISniA'fivE DETAII
Philip Lon8sttff FCA
ICAEW
Ellis Atkins
Chartered Aceountants
The Atrium Busin&ss Centre
CU￿$ Road
Dothing
Surrey
RE14 IX4
Ex¢¢utlve Members
Dr IAui5e Smart
Dr Ash Chandra
Mr5 Helen Burrell
Mr Eledley Glencross
Ms Alison m￿kIll
DrYuTina Miki
Ms L¢oni¢ Glinski
Co-opl*l Members
Prof&%50rMichael Sheaff
MTS Sharon Robelts￿an1
Ms Kir5tie Rice
Mts Eva Halbtan
Approved by orderof the Ixiard of tn]sttos0n_........:. .....
. and signed on its bEhalf by:
Mrs A Croppcr. TnL
PagE 5

INDEPENDENT E?&AMINER'S REPORT TO THE TRUSTEES OF
BRITISH ASSOCIATION FOR CYTOPATHOLOGY
Independent exAminer's report to tbe truslee8 of Brit15h Assoclatlon forCytop4thology
I rewrt to the charity trustees on my examination of the accounts of British A550ciation for C￿0pathO]0gY (the Trust)
forthe year ended 31 Marth 2021.
Responsibilities and bAsls of report
As th¢ charity truste¢3 of th¢ Trust yvu are resyK)nsible for the preparation of the accounts in ￿CordanCe with lh¢
reqU1￿ments of the Charitieb ALt 2011 ('thc Act).
I rew>rt in resp¢ci of my examination of the 1'rusl's accounts carried out under 3C¢ti¢)n 145 of ihe Act and in Carrying oiit
my examination I have tollowed all applicablc Dir¢clLoll5 given by the Charity Commission und¢r section 145(5llb) of
the Act.
Independent tx#mlner's ytAtemcnt
I have ¢omplet¢d my examination. I confimi that DO mat¢ri81 mattér5 have come to my att¢ntion in connection with ihe
exan)itJation giving me cuusc to believe that in any material respect..
a¢counting ￿CordS w¢r¢ not k¢pl in r¢5pect of the Ttwt as requird by section 130 of the Act,. or
the accounts du Iiul a¢¢ord with thu5e records. or
th¢ a¢¢ounts do not coinply with Ih¥ w)plicablc requirements eonc¢ming the form and contcnt of accounis sel oul
in the Chllritics (Accounts and R¢ports) Regulations 2008 other thart Any requirement that tile accounis a
e and foir vicw which is not u rnatter considcred as port of independent examination.
I havc no concems and have coine across no oih¢r matters in ¢onn¢rtiQlJ Wlth the examination to which altcnlion sliould
be drnwn in this Teport in ord¢r ￿ en&blL a proper understsndin8 of the accounts to b¢ reach￿.
Philip LOn￿stsff FCA
ICAEW
Ellis Atkin$
C.har(ered ALcoiinianls
ThL Atrium Bugine55 CciJtr
C.uriis Rofid
Dorking
RH4 IXA
D81¢'.
Pog¢ 6

## **BRITISH ASSOCIATION FOR CYTOPATHOLOGY** 

## **STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2021** 

|**31/3/21**<br>**Unrestricted**<br>**fund**<br>Notes<br>**£**<br>**INCOME AND ENDOWMENTS FROM**<br>**Charitable activities**<br>3<br>Advancement of scientific research<br>**56,946**<br>Investment income<br>2<br>**348**<br>**Total**<br>**57,294**<br>**EXPENDITURE ON**<br>**Charitable activities**<br>4<br>Advancement of scientific research<br>**52,289**<br>Net gains/(losses) on investments<br>**7,752**<br>**NET INCOME/(EXPENDITURE)**<br>**12,757**<br>**RECONCILIATION OF FUNDS**<br>**Total funds brought forward**<br>**401,974**<br>**TOTAL FUNDS CARRIED FORWARD**<br>**414,731**|31/3/20<br>Total<br>funds<br>£<br>68,720<br>382<br>69,102<br>71,401<br>(4,858)<br>(7,157)<br>409,131<br>401,974|
|---|---|



The notes form part of these financial statements 

Page 7 



BIUIISH ASSOCIATIOY FOR cYfopATHOIKIGY
4LA.NCE SHEET
31 MARCH 2021
310tt1
3113QO
To¢al
Tangiblc
847
3iJ07
23,555
24
CURREprr KSSETS
io
Cth atbAnk
9JI28
YJ1667
10395
385JOJ
596￿9$
CREDTrois
AM¢￿ts fallin8 due within t￿Y
(IV18)
(18.808)
3W77
377,Xl
LIABILITIES
414731
401.974
414,7JA
4101,974
12
UnreAria¢d fijn
414,rJi
401,974
414,731
401.974
Tr rIn￿¢181 51atanents wae mrov¥J by the &)8fd of Tw5WS 8NI .
atsj we¥e$L￿d th itslrhRJf by..
K Ell￿- TNst¢e

**BRITISH ASSOCIATION FOR CYTOPATHOLOGY** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2021** 

## **1. ACCOUNTING POLICIES** 

## **Basis of preparing the financial statements** 

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention, with the exception of investments which are included at market value, as modified by the  revaluation of certain assets. 

The financial statements present information about the charity as an individual undertaking and not as a group. 

There are no material uncertainties regarding the charity's ability to continue as a going concern. 

## **Income** 

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably. 

## **Expenditure** 

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources. 

## **Allocation and apportionment of costs** 

The charity allocates its support costs on a basis consistent with the use of resources. 

## **Tangible fixed assets** 

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life. 

Website development - 33% on cost Plant and machinery - 25% on cost Computer equipment - 33% on cost 

## **Taxation** 

The charity is exempt from tax on its charitable activities. 

## **Fund accounting** 

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees. 

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes. 

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements. 

continued... 

Page 9 



**BRITISH ASSOCIATION FOR CYTOPATHOLOGY** 

## **NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2021** 

|**2.**|**INVESTMENT INCOME**|||||
|---|---|---|---|---|---|
|||||**31/3/21**|31/3/20|
|||||**£**|£|
||Deposit account interest|||**348**|382|
|**3.**|**INCOME FROM CHARITABLE ACTIVITIES**|||||
|||||**31/3/21**|31/3/20|
|||Activity||**£**|£|
||Subscriptions|Advancement of scientific research||**22,401**|25,114|
||Tutorial and ASM income|Advancement of scientific research||**-**|430|
||Journal royalties|Advancement of scientific research||**34,545**|43,176|
|||||**56,946**|68,720|
|**4.**|**CHARITABLE ACTIVITIES**|**COSTS**||||
|||||Support||
||||Direct|costs (see||
||||Costs|note 5)|Totals|
||||£|£|£|
||Advancement of scientific research||**19,642**|**32,647**|**52,289**|
|**5.**|**SUPPORT COSTS**|||||
|||||Governance||
||||Management|costs|Totals|
||||£|£|£|
||Advancement of scientific research||**29,707**|**2,940**|**32,647**|
||Support costs, included in the above, are as follows:|||||
|||||**31/3/21**|31/3/20|
|||||Advancement||
|||||of||
|||||scientific|Total|
|||||research|activities|
|||||**£**|£|
||Office costs|||**3,191**|**2,965**|
||Travel|||**1,672**|**9,004**|
||Administration costs|||**24,000**|**22,000**|
||Subscriptions|||**384**|**336**|
||Depreciation of tangible assets|||**282**|**376**|
||Interest payable and similar charges|||**178**|**137**|
||Independent Examiner's Fee|||**2,940**|**2,940**|
|||||**32,647**|**37,758**|



continued... 

Page 10 



**BRITISH ASSOCIATION FOR CYTOPATHOLOGY** 

## **NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2021** 

## **6. INDEPENDENT EXAMINER' S REMUNERATION** 

|**INDEPENDENT EXAMINER' S REMUNERATION**|||
|---|---|---|
||**31/3/21**|31/3/20|
||**£**|£|
|Independent Examiner's Fee|**2,940**|2,940|



Independent examiners remuneration for the year was £2,940 (2020: £2,940). 

## **7. TRUSTEES' REMUNERATION AND BENEFITS** 

There were no trustees' remuneration or other benefits for the year ended 31 March 2021 nor for the year ended 31 March 2020. 

## **Trustees' expenses** 

Details relating to trustees' expenses are given below. 

## **Executive members** 

Travelling and directly incurred other expenses amounting to £953 were reimbursed to 2 Executive Members (2020 - £5,757 to 11 Executive Members). This includes £953 reimbursed to 2 trustees (2020- £4,374 to 6 trustees). 

There were no staff directly employed during the year or previous period. 

## **8. TANGIBLE FIXED ASSETS** 

|Website<br>Plant and<br>Computer<br>development<br>machinery<br>equipment<br>£<br>£<br>£<br>**COST**<br>At 1 April 2020 and 31 March 2021<br>**17,626**<br>**6,339**<br>**524**<br>**DEPRECIATION**<br>At 1 April 2020<br>**17,626**<br>**5,210**<br>**524**<br>Charge for year<br>**-**<br>**282**<br>**-**<br>At 31 March 2021<br>**17,626**<br>**5,492**<br>**524**<br>**NET BOOK VALUE**<br>At 31 March 2021<br>**-**<br>**847**<br>**-**<br>At 31 March 2020<br>-<br>1,129<br>-|Totals<br>£<br>**24,489**|
|---|---|
||**23,360**<br>**282**|
||**23,642**|
||**847**|
||1,129|



continued... 

Page 11 



## **BRITISH ASSOCIATION FOR CYTOPATHOLOGY** 

## **NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2021** 

## **9. FIXED ASSET INVESTMENTS** 

|**MARKET VALUE**<br>At 1 April 2020<br>Revaluations<br>At 31 March 2021<br>**NET BOOK VALUE**<br>At 31 March 2021<br>At 31 March 2020<br>There were no investment assets outside the UK.<br>Cost or valuation at 31 March 2021 is represented by:<br>Valuation in 2021<br>The market value is represented by the quoted market price at 31st March 2021.<br>**10.**<br>**DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**<br>Accrued royalty income<br>**11.**<br>**CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**<br>Accruals and deferred income<br>Prepaid subscriptions<br>**12.**<br>**MOVEMENT IN FUNDS**<br>At 1.4.20<br>£<br>**Unrestricted funds**<br>General fund<br>**401,974**<br>**TOTAL FUNDS**<br>**401,974**|Listed<br>investments<br>£<br>**23,555**<br>**7,752**<br>**31,307**<br>**31,307**<br>23,555<br>**Listed**<br>**investments**<br>**£**<br>**31,307**<br>**31/3/21**<br>31/3/20<br>**£**<br>£<br>**9,028**<br>10,595<br>**31/3/21**<br>31/3/20<br>**£**<br>£<br>**9,510**<br>7,763<br>**10,608**<br>11,045<br>**20,118**<br>18,808<br>Net<br>movement<br>At<br>in funds<br>31.3.21<br>£<br>£<br>**12,757**<br>**414,731**<br>**12,757**<br>**414,731**|
|---|---|



continued... 

Page 12 



## **BRITISH ASSOCIATION FOR CYTOPATHOLOGY** 

## **NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2021** 

## **12. MOVEMENT IN FUNDS - continued** 

Net movement in funds, included in the above are as follows: 

||Incoming|Resources|Gains and|Movement|
|---|---|---|---|---|
||resources|expended|losses|in funds|
||£|£|£|£|
|**Unrestricted funds**|||||
|General fund|**57,294**|**(52,289)**|**7,752**|**12,757**|
|**TOTAL FUNDS**|**57,294**|**(52,289)**|**7,752**|**12,757**|



## **Comparatives for movement in funds** 

|**Unrestricted funds**<br>General fund<br>**TOTAL FUNDS**|At 1.4.19<br>£<br>409,131<br>409,131|Net<br>movement<br>in funds<br>£<br>(7,157)<br>(7,157)|At<br>31.3.20<br>£<br>401,974|
|---|---|---|---|
||||401,974|



Comparative net movement in funds, included in the above are as follows: 

||Incoming|Resources|Gains and|Movement|
|---|---|---|---|---|
||resources|expended|losses|in funds|
||£|£|£|£|
|**Unrestricted funds**|||||
|General fund|69,102|(71,401)|(4,858)|(7,157)|
|**TOTAL FUNDS**|69,102|(71,401)|(4,858)|(7,157)|



A current year 12 months and prior year 12 months combined position is as follows: 

|**Unrestricted funds**<br>General fund<br>**TOTAL FUNDS**|At 1.4.19<br>£<br>409,131<br>409,131|Net<br>movement<br>in funds<br>£<br>5,600<br>5,600|At<br>31.3.21<br>£<br>414,731|
|---|---|---|---|
||||414,731|



continued... 

Page 13 



## **BRITISH ASSOCIATION FOR CYTOPATHOLOGY** 

## **NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2021** 

## **12. MOVEMENT IN FUNDS - continued** 

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows: 

||Incoming|Resources|Gains and|Movement|
|---|---|---|---|---|
||resources|expended|losses|in funds|
||£|£|£|£|
|**Unrestricted funds**|||||
|General fund|126,396|(123,690)|2,894|5,600|
|**TOTAL FUNDS**|126,396|(123,690)|2,894|5,600|



The association only operates one general fund. This is used for the general and scientific activities of BAC. 

## **13. RELATED PARTY DISCLOSURES** 

There were no related party transactions for the year ended 31 March 2021. 

Page 14